Shire Is Agnostic On Baxalta's Biosimilars Pipeline As Integration Begins

In an interview, CEO Ornskov notes that prioritization of combined company's assets is only just beginning with closing of the $32bn merger.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America